United Neuroscience (UNS) has reported positive top-line results from its Phase IIa clinical trial evaluating UB-311 in patients with Alzheimer’s disease.

The trial met its primary endpoint of safety and immunogenicity with a 96% response rate.

Secondary endpoints of the trial also achieved favourable results, but not statistically significant data among the study patients.

The trial’s secondary endpoints included amyloid PET burden, clinical dementia rating sum of boxes (CDR-SB), Alzheimer’s disease cooperative study activities of daily living inventory (ADCS-ADL) and mini–mental state examination (MMSE).

United Neuroscience research and development executive vice-president Peter Powchik said: “The positive results show that we can safely raise and maintain anti-Aβ antibody titers in a predictable and sustained manner.

“The intent of this Phase IIa study was to acquire directional information on the safety, tolerability and therapeutic potential of UB-311.”

“High response rates, reproducibility of response and generation of antibodies directed to relevant toxic protein species are key elements of an effective therapeutic vaccine for neurodegenerative conditions.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“The UNS platform is proving that it can deliver on these requirements.”

UNS’ Phase IIa trial was conducted in a double-blinded, placebo-controlled setting. It examined the safety and immunogenicity of two different dosing regimens of UB-311.

Subjects from the trial will also take part in a long-term extension study and will continue to receive UB-311.

United Neuroscience CEO Mei Mei Hu said: “These early results suggest a clinical response and support the continued and rapid development of UB-311.

“The intent of this Phase IIa study was to acquire directional information on the safety, tolerability and therapeutic potential of UB-311 in patients with Alzheimer’s disease.”